Coya Therapeutics, Inc.
↗Houston, USA
Coya Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Houston, Texas, focused on developing proprietary therapies to enhance the function of regulatory T cells (Tregs). The company aims to address systemic inflammation and neuroinflammation, which are underlying factors in various neurodegenerative, autoimmune, and metabolic diseases.
The company's pipeline leverages multiple therapeutic modalities, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Its lead candidate, COYA 302, is a biologic combination therapy currently in Phase 2 clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) and is being investigated for other neurodegenerative conditions like frontotemporal dementia and Alzheimer's disease.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Neurodegenerative diseases, Autoimmune diseases
SIZE & FINANCIALS
Employees:1-50
Revenue:$1M-$10M
Founded:2020
Ownership:public
Status:operating
FUNDING
Stage:Public
STOCK
Exchange:NASDAQ
Ticker:COYA
Market Cap:$0.09B
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Biologics, Exosomes, Cell therapy
Active Trials:1
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Dr. Reddy's Laboratories SA (development and commercialization of COYA 302), NEALS Consortium (NEALS-Affiliated Trial for COYA 302)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Arun Swaminathan - CEO
LINKS
Website:coyatherapeutics.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Coya Therapeutics, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Coya Therapeutics, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.